참고문헌
- Schhnnberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988;29:1790-4
- Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37: 1468-72
- Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52 https://doi.org/10.1007/s002590050493
-
Hooft L, van der Veldt AA, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ, et al. [
$^{18}F$ ]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase expression in the primary tumor. J Din Endocrinol Metab 2005;90:328-34 https://doi.org/10.1210/jc.2004-0779 - Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:1342-8 https://doi.org/10.1007/s002590050158
-
Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, et al. [
$^{18}F$ ]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic ($^{131}$ )I whole body scans and elevated serum thyroglobulin levels. J Clin Endncrinol Metab 1999;84:2291-302 https://doi.org/10.1210/jc.84.7.2291 - Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616-24
- Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol 2007;14:730-8 https://doi.org/10.1245/s10434-006-9207-5
- Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000;257:231-7 https://doi.org/10.1006/excr.2000.4888
- Novosel I, Bulimbasic S, Ramljak V, Matkovic B, Dosen D, Separovic V. p53, bcl-2 and Ki-67 in the diagnosis of insular thyroid gland cancer. Case report with a review of literature. Lijec Vjesn 2006; 128:264-7
- Mu DB, Wang SP, Yang WF, Fu Z, Chen XX, Sun XR, et al. Correlation between FDG PET/CT and the expression of glutl and ki-67 antigen in esophageal cancer. Zhonghua Zhong Liu Za Zhi 2007;29:30-3
- Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 2008;3:971-8 https://doi.org/10.1097/JTO.0b013e31818307a7
- Lemoine NR, Hughes CM, Gullick WJ, Brown CL, Wynford-Thomas D. Abnormalities of the EGF receptor system in human thyroid neoplasia. Int J Cancer 1991;49:558-61 https://doi.org/10.1002/ijc.2910490414
- Westermark K, Lundqvist M, Wallin G, Dahlman T, Hacker GW, Heldin NE, et al. EGF-receptors in human normal and pathological thyroid tissue. Histopathology 1996;28:221-7 https://doi.org/10.1046/j.1365-2559.1996.d01-427.x
- Dub QY, Gum ET, Gerend PL, Raper SE, Clark OH. Epidermal growth factor receptors in normal and neoplastic thyroid tissue. Surgery 1985;98:1000-7
- Nicholson S, Richard J, Sainsbury C, Halcrow P, Kelly P, Angus B, et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991;63:146-50
- Akslen LA, Myking AO, Salvesen H, Varhaug JE. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br J Cancer 1993;68:808-12 https://doi.org/10.1038/bjc.1993.432
- Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204
- Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4
- Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L, Fahey TJ 3rd. Cyclooxygenase-2 expression in thyroid nodules. J Din Endocrinol Metab 2002;87:358-63 https://doi.org/10.1210/jc.87.1.358
- Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80
- Siironen P, Ristimaki A, Nordling S, Louhimo J, Haapiainen R, Haglund C. Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology 2004;44:490-7 https://doi.org/10.1111/j.1365-2559.2004.01880
- Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 2003;42:492-7 https://doi.org/10.1046/j.1365-2559.2003.01624.x
- Cornetta AJ, Russell JP, Cunnane M, Keane WM, Rothstein JL. cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope 2002; 112:238-42 https://doi.org/10.1097/00005537-200202000-00008
- Nose F, Ichikawa T, Fujiwara M, Okayasu I. Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase. Am J Clin Pathol 2002;117:546-51 https://doi.org/10.1309/9CCJ-XQ8P-PMFM-M65K
-
Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M, et al. Comparison of
$^{18}F$ -FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 2007;48:889-95 https://doi.org/10.2967/jnumed.106.039479 - Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996;56:4530-4
- Kuwabara I, Liu FT. Galectin-3 promotes adhesion of human neutrophils to laminin. J Immunol 1996;156:3939-44
- Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996;93:6737-42 https://doi.org/10.1073/pnas.93.13.6737
- Raz A, Zhu DG, Hogan V, Shah N, Raz T, Karkash R, et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 1990;46:871-7 https://doi.org/10.1002/ijc.2910460520
- Nangia-Makker P, Sarvis R, Visscher DW, Bailey-Penrod J, Raz A, Sarkar FH. Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Res Treat 1998;49:171-83 https://doi.org/10.1023/A:1005913810250
- Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 2000;31:428-33 https://doi.org/10.1053/hp.2000.6534
- Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999;59:4148-54
- Yamazaki K, Kawai A, Kawaguchi M, Hibino Y, Li F, Sasahara M, et al. Simultaneous induction of galectin-3 phosphorylated on tyrosine residue, p21 (WAF1/Cip1/Sdi1), and the proliferating cell nuclear antigen at a distinctive period of repair of hepatocytes injured by CCl4. Biochem Biophys Res Commun 2001;280: 1077-84 https://doi.org/10.1006/bbrc.2000.4193
- Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, Semeraro ML, et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000;85:545-54 https://doi.org/10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N
- Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1(NWGR) domain of Bcl-2 family. Cancer Res 1997;57:5272-6
- Liu FT, Rabinovich GA. Gdlectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29-41 https://doi.org/10.1038/nrc1527
- Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucantc T, Khan A, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-50 https://doi.org/10.1016/S0140-6736(00)04817-0
- De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002;29:525-9 https://doi.org/10.1007/s00259-001-0743-8
-
Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body
$^{18}F$ -Foo PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-63 -
Miller TR, Pinkus E, Dehdashti F, Grigsby PW. Improved prognostic value of
$^{18}F$ -FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med 2003;44: 192-7 - Padrna MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227-37 https://doi.org/10.1023/A:1025665820001
-
Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [
$^{18}F$ ]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003;30:78-84 https://doi.org/10.1007/s00259-002-0937-8